Search results
Jun 11, 2024 · Across all age groups, the updated bivalent booster vaccines showed superior effectiveness against symptomatic and asymptomatic Omicron infection when compared with both 2 or more (VE, 30.8%; 95% CI, 22.5-38.2; I 2 =99.4%) and 3 or more (VE, 41.8%; 95% CI, 9.0-62.8; I 2 =99.7%) monovalent doses.
6 days ago · The booster dose raised vaccine efficacy against omicron to a maximum of 70.1% (at 2-4 weeks after booster with mRNA-1273) for the ChAdOx1 vaccine. Responses to the mRNA-based vaccine booster were similar for the BNT162b2 and mRNA-1273 primary series vaccines.
6 days ago · The researchers studied 76 SOTRs who had received a minimum of three doses of a primary monovalent (active against just the original SARS-CoV-2 strain) mRNA vaccine, reported receiving either one or two bivalent mRNA vaccine boosters (containing both the original strain and the omicron BA.5 variant), and provided two or more blood samples that were obtained pre- and post-bivalent booster in ...
Jun 20, 2024 · How does Paxlovid work? Paxlovid is an antiviral therapy that consists of two separate medications packaged together. When you take your three-pill dose, two of those pills will be nirmatrelvir, which inhibits a key enzyme that the COVID virus requires in order to make functional virus particles.
- kathy.katella-cofrancesco@yale.edu
Jun 17, 2024 · Omalizumab is not associated with an increased risk of infection nor increases the risk for COVID-19. If you are taking omalizumab for asthma, nasal polyps, or urticaria you are not at increased risk for allergic reactions after the COVID-19 vaccination.
6 days ago · People 18 years of age and older can receive a booster dose with any available mRNA COVID-19 vaccine as to date, there has not been a difference between Pfizer and Moderna in terms of the risk of myocarditis and/or pericarditis following booster doses.
Jun 13, 2024 · Our results show that Omicron breakthrough infection : Triggered stronger and more broadly effective antibody responses in the blood than vaccination alone in people who had not been infected before. Boosted T-cell responses, even in those who had been infected with SARS-CoV-2 before vaccine rollout.
